Cardiogen 20mg

Cardiogen is the cardiac-targeted tripeptide (Ala-Glu-Asp) from the Khavinson bioregulatory series. Same sequence as Bronchogen, different tissue target — in the Khavinson framework, tissue specificity emerges from distribution following administration rather than from sequence alone. Cardiomyocytes are the intended research context here: myocardial aging, cardiac fibrosis, and the gene expression changes associated with cardiomyocyte senescence.

Cardiac muscle presents a specific biological challenge. Cardiomyocytes are largely post-mitotic in adults — cardiomyocyte loss from aging or injury is mostly irreversible, unlike in regenerative tissues. The transcriptional programs that govern cardiomyocyte function, mitochondrial capacity, and extracellular matrix production change significantly with age. The research question Cardiogen is positioned to address: can short peptide bioregulation influence those transcriptional programs in a tissue-targeted way? The Khavinson group has published on cardiac bioregulators for several decades with that question in mind. As with the broader series, the data comes primarily from their institute, and independent replication is limited.

Research Applications

Published endpoints examined in Khavinson cardiac bioregulator research include mitochondrial function in aging cardiac tissue, anti-fibrotic signaling, cardiomyocyte protein synthesis rates, and age-related changes in cardiac gene expression profiles. For researchers in the cardiovascular aging space, Cardiogen can be studied alongside Vesugen (vascular endothelium target) for comparative tissue-level gene regulation research.

Specifications

Storage: Lyophilized: −20°C, away from light. Once reconstituted: 2–8°C, use within 4 weeks.

Quality: HPLC purity analysis, mass spec identity confirmation, endotoxin testing on every batch. COA ships with every order. EU-based QC under CERTALAB S.R.L.

For research purposes only. Not for human consumption.